Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2025
0mins
Clinical Trial Results: UNITY Biotechnology's Phase 2b ASPIRE trial showed that UBX1325 is non-inferior to aflibercept in improving vision for patients with diabetic macular edema, particularly benefiting those with moderately aggressive disease.
Safety Profile: The treatment demonstrated a favorable safety and tolerability profile, with no reported cases of serious complications such as intraocular inflammation or retinal artery occlusion across multiple studies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
